Reviving pegylated interferon as a therapeutic agent for hepatitis D: No more room for nucleos(t)ides?

Hepatology

Volumn 53, Issue 6, 2011, Pages 2131-2134

  Lutz, Holger H ^a   Trautwein, Christian ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; NUCLEOSIDE; NUCLEOTIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; VIRUS RNA;

DELTA AGENT HEPATITIS; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HEPATITIS; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; SUPERINFECTION; VIRAL CLEARANCE; VIRUS HEPATITIS;

EID: 79957508697     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24311     Document Type: Note

References (24)

1. Handa H, Yamaguchi Y. Hepatitis Delta Virus. New York, NY: Springer; 2006.
2. Nakano T, Shapiro CN, Hadler SC, Casey JL, Mizokami M, Orito E, et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol 2001; 82( pt 9): 2183-2189.
3. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010; 53: 834-840.
4. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-1638.
5. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloǧlu Y, Deǧertekin H, et al.; for HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331.
6. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. HEPATOLOGY 2006; 44: 728-735.
7. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. HEPATOLOGY 2006; 44: 713-720.
8. Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006; 12: 1447-1450.
9. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-1635.
10. Kiesslich D, Crispim MA, Santos C, Ferreira Fde L, Fraiji NA, Komninakis SV, et al. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J Infect Dis 2009; 199: 1608-1611.
11. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
12. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006; 13: 505-514.
13. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. HEPATOLOGY 1991; 13: 1052-1056.
14. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol 2009; 90( pt 11): 2759-2767.
15. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30: 430-437.
16. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. HEPATOLOGY 2010; 52: 1251-1257.
17. Wedemeyer H. Differential cytokine pattern of HDV-specific cellular immune responses distinguishes treatment responder and nonresponder to peg-IFN alpha-2a treatment: results from the HEP-NET/international HIDIT-1 study. J Hepatol 2007; 46( Suppl): S13-S14.
18. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 2008; 13: 97-102.
19. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112: 407-414.
20. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. HEPATOLOGY 2006; 43: 750-760.
21. Herkel J, Jagemann B, Wiegard C, Lazaro JF, Lueth S, Kanzler S, et al. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocytes. HEPATOLOGY 2003; 37: 1079-1085.
22. Pugnale P, Pazienza V, Guilloux K, Negro F. Hepatitis delta virus inhibits alpha interferon signaling. HEPATOLOGY 2009; 49: 398-406.
23. Liao FT, Lee YJ, Ko JL, Tsai CC, Tseng CJ, Sheu GT. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. J Gen Virol 2009; 90( pt 5): 1124-1134.
24. Park CY, Oh SH, Kang SM, Lim YS, Hwang SB. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling. Mol Cells 2009; 28: 49-55.